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Evaluation of prevalence, biochemical profile, and drugs 
associated with chronic kidney disease-mineral and bone 
disorder in 11 dialysis centers
Avaliação da prevalência, perfil bioquímico e drogas associadas 
ao distúrbio mineral ósseo-doença renal crônica em 11 centros de 
diálise
Introdução: O diagnóstico e tratamento 
do distúrbio mineral ósseo-doença renal 
crônica (DMO-DRC) é um desafio para os 
nefrologistas e gestores de saúde. O objetivo 
deste estudo foi avaliar a prevalência, perfil 
bioquímico, e drogas associadas a DMO-
DRC. Métodos: Estudo transversal entre jul-
ho e novembro de 2013, em 11 centros com 
1134 pacientes em diálise. Dados sociode-
mográficos, clínicos, e laboratoriais foram 
comparados entre os grupos, com base em 
níveis do paratormônio intacto (PTHi) (< 
150,151-300, 301-600,601-1000, e > 1001 
pg/mL). Resultados: A idade média foi de 
57,3 ± 14,4 anos, 1071 pacientes estavam 
em hemodiálise, e 63 em diálise peritoneal. 
A prevalência de PTHi < 150 pg/mL foi 
23,4% e PTHi > 601 pg/mL foi de 27,1%. 
A comparação dos grupos mostrou que o 
nível de PTHi diminuiu com o aumento da 
idade. Pacientes diabéticos apresentaram 
uma maior prevalência de PTHi < 150 pg/
mL (27,6%). Carbonato de cálcio foi usado 
por 50,5%, Sevelamer por 14,7%, 40% 
dos pacientes utilizaram alguma forma de 
vitamina D, e 3,5% utilizaram cinacalcet. A 
hiperfosfatemia (> 5,5mg/dL) foi observada 
em 35,8%. A análise de regressão linear 
mostrou uma associação negativa significa-
tiva entre PTHi, idade, e diabetes mellitus e 
uma associação positiva significativa com o 
tempo em diálise. Conclusão: A prevalência 
de pacientes fora do alvo para PTHi foi de 
50,5%. Houve uma alta prevalência de hi-
perfosfatemia e um baixo uso de vitamina 
D ativa, análogos da vitamina D, ativadores 
seletivos da vitamina D, e cinacalcet. Estes 
dados chamam a atenção para a neces-
sidade de uma maior conformidade com as 
diretrizes e políticas públicas sobre o for-
necimento de medicamentos associados à 
DMO-DRC.
Resumo
Palavras-chave: Falência renal crônica; 
diálise renal; doenças ósseas.
Introduction: The diagnosis and treatment 
of mineral and bone disorder of chronic 
kidney disease (CKD-MBD) is a challenge 
for nephrologists and health managers. 
The aim of this study was to evaluate the 
prevalence, biochemical profile, and drugs 
associated with CKD-MBD. Methods: 
Cross-sectional study between July and 
November 2013, with 1134 patients on 
dialysis. Sociodemographic, clinical, and 
laboratory data were compared between 
groups based on levels of intact parathy-
roid hormone (iPTH) (< 150, 150-300, 
301-600, 601-1000, and > 1001 pg/mL). 
Results: The mean age was 57.3 ± 14.4 
years. The prevalence of iPTH < 150 pg/
mL was 23.4% and iPTH > 601 pg/mL 
was 27.1%. The comparison between the 
groups showed that the level of iPTH de-
creased with increasing age. Diabetic pa-
tients had a higher prevalence of iPTH < 
150 pg/mL (27.6%). Hyperphosphatemia 
(> 5.5 mg/dL) was observed in 35.8%. 
Calcium carbonate was used by 50.5%, 
sevelamer by 14.7%, 40% of patients had 
used some form of vitamin D and 3.5% 
used cinacalcet. Linear regression analy-
sis showed a significant negative asso-
ciation between iPTH, age, and diabetes 
mellitus and a significant positive asso-
ciation between iPTH and dialysis time. 
Conclusion: The prevalence of patients 
outside the target for iPTH was 50.5%. 
There was a high prevalence of hyper-
phosphatemia (35.8%), and the minority 
of patients were using active vitamin D, 
vitamin D analogs, selective vitamin D 
receptor activators, and cinacalcet. These 
data indicate the need for better compli-
ance with clinical guidelines and public 
policies on the supply of drugs associated 
with CKD-MBD.
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IntRoductIon
Brazil is the largest country in Latin America, and the 
only country over 100 million people with a public 
health system (SUS) that assures universal access to 
health care since 1990. According to the Brazilian 
Institute of Geography and Statistics (IBGE), in 2015 
Brazil had a population of 203,980,840 million peo-
ple, with a human development index of 0.749 and 
life expectancy of 74.9 years1. The country is under-
going a demographic change characterized by popu-
lation ageing, with the elderly comprising 31 mil-
lion people. The prevalence of arterial hypertension 
among the population over 40 years old is 40%-50%2. 
According to the International Diabetes Federation, 
there are nearly 11.6 million diabetic individuals in 
Brazil3. Since the Brazilian Dialysis Survey was cre-
ated by the Brazilian Society of Nephrology, the num-
ber of people on dialysis in the country has increased 
progressively, and was estimated to be 100,397 in the 
2013 survey4.
One of the comorbidities associated with CKD is 
the mineral and bone disorder (CKD-MBD), a syn-
drome which encompasses clinical, biochemical (cal-
cium, phosphate, parathyroid hormone, and active vi-
tamin D), and bone abnormalities (bone remodeling, 
mineralization, and bone volume), in addition to the 
comorbidities associated with extra-skeletal calcifica-
tion and cardiovascular disturbances5. The broadly 
used term ‘renal osteodystrophy’ is currently used to 
define changes in bone histology evaluated by biop-
sy5. Based on bone remodeling, renal osteodystrophy 
is classified as either a high remodeling bone disease 
(secondary hyperparathyroidism or osteitis fibrosa) 
or a low remodeling bone disease (represented by os-
teomalacia and adynamic bone disease). In addition, 
a mixed bone disease can occur, which presents both 
high and low remodeling characteristics and is cur-
rently classified as high remodeling5.
Most evidence shows that adynamic bone disease 
characterized by low bone turnover occurs in the 
early stages of chronic kidney disease in a significant 
proportion of patients. This could be due to the ini-
tial predominance of bone turnover inhibitory con-
ditions such as resistance to parathyroid hormone 
(PTH), reduced calcitriol levels, sex hormone defi-
ciency, diabetes mellitus, and uremic toxins leading 
to suppression of various means of bone signaling. 
In later stages, osteitis fibrosa, a high-turnover bone 
disease, develops resulting mainly from secondary 
hyperparathyroidism6.
In 1998, Diaz Lopez et al. evaluated the epidemi-
ology of renal osteodystrophy in 1209 bone biopsies 
from patients in five Ibero-American countries (Brazil, 
Uruguay, Argentina, Portugal, and Spain) and showed 
that hyperparathyroidism was more frequent in pa-
tients on dialysis in Spain and Portugal (66 and 70%, 
respectively), whereas mixed and low-bone remodel-
ing lesions accounted for less than 14%. On the other 
hand, South American patients showed a high preva-
lence of mixed and low-bone remodeling lesions (37 
and 51%, respectively)7. The study by Araújo SM et 
al. evaluated the prevalence of CKD-MBD in dialysis 
patients in Brazil and Uruguay and showed, through 
bone biopsy, an increase of prevalence of second-
ary hyperparathyroidism from 32.3% in 1985-1990 
to 44% in 1997-2000 in 2,340 Brazilian patients8. 
According to data from the 2011 Brazilian Census of 
Parathyroidectomy, the prevalence of severe second-
ary hyperparathyroidism was 10.7%, based on levels 
of intact parathyroid hormone (iPTH) higher than 
1000 pg/mL, indicative of parathyroidectomy9.
A study published in 2011 and conducted in he-
modialysis centers in Argentina, Chile, Colombia, 
Venezuela, Mexico, and Brazil (CORES Study) in-
volving 16,173 patients analyzed the impact of cal-
cium, phosphate, and iPTH levels in mortality and 
concluded that low or high serum levels of all vari-
ables raised the risk of death10. Abnormalities in se-
rum phosphorus, calcium, and parathyroid hormone 
have been associated with poor survival in dialysis 
patients. A total of 4,500 patients were randomly re-
cruited for COSMOS study from 227 dialysis centers 
in 20 European countries. In summary, a non-linear 
relationship was found between serum CKD-MBD 
biochemical parameters and mortality risk. Low and 
high serum levels of serum phosphorus, calcium, and 
PTH were associated with a higher relative risk of 
mortality while decreases in serum phosphorus and 
calcium and increases in serum PTH during follow-
up were associated with a significant lower risk of 
mortality11.
iPTH levels below 150 pg/mL were seen in 36% 
of 3,226 incident and prevalent patients treated with 
peritoneal dialysis in Brazil (continuous ambulatory 
peritoneal dialysis or automated peritoneal dialysis)12.
Historically, renal osteitis fibrosa and mixed ure-
mic osteodystrophy were the most prevalent bone 
diseases in patients with CKD. Recently, an increase 
in the prevalence of adynamic bone disease has been 
observed, particularly in diabetic patients6,13.
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Although abundant, the studies cited above show 
partial data or were based on patients followed in a 
reference center for CKD-MBD, thus are subject to 
bias. The evaluation of CKD-MBD patterns, practic-
es, and epidemiology is fundamental for public health 
programs. In Brazil, there are considerable difficulties 
in keeping records on specific pathologies and, espe-
cially, planning strategies based on accurate informa-
tion. Thus, studies assessing occurrences in the vari-
ous regions of the country, characterized by different 
realities, are vital for better healthcare planning. Since 
there is a lack of an extensive evaluation of patients 
on hemodialysis (HD) and peritoneal dialysis PD in 
Brazil, the aim of this study was to evaluate the preva-
lence, biochemical profile, and drugs associated with 
CKD-MBD in these patients.
mAteRIAl And methods
study desIgn and settIng
We performed a cross-sectional study in 11 nephrolo-
gy centers run by the Nephrology Centers Association 
of the State of Minas Gerais (Associação Mineira de 
Centros de Nefrologia - AMICEN), which covers 
2,371,572 people14. The association includes 19 renal 
replacement therapy (RRT) centers, distributed across 
the East, South, Northeast, Midwest and central areas 
of Minas Gerais, Brazil.
The present study was performed according to 
the Declaration of Helsinki and approved by the 
Ethics and Research Committee of the Hospital 
of the Federal University of Juiz de Fora, Brazil 
(Universidade Federal de Juiz de Fora), under the fol-
lowing number: 21702913.9.0000.5147.
study populatIon
The inclusion criteria were patients with CKD over 
18 years old on dialysis (HD or PD) for more than 3 
months, with at least one iPTH dosage in 2013 and 
who have signed the informed consent form. The ex-
clusion criteria were patients less than 18 years old 
and who were missing laboratorial iPTH dosage 
within the period of study.
study procedures and MeasureMents
Data were based on medical records and on the labo-
ratorial evaluation obtained in July and November 
2013. For this purpose, the NEFRODATA® soft-
ware (medical registry) was used. The following so-
cio-demographic variables were analyzed: age, sex, 
race, income, and level of education (according to 
the IBGE). The following clinical variables were ana-
lyzed: CKD etiology, associated comorbidities, and 
dialysate calcium concentration. Laboratorial vari-
ables included hemoglobin (g/dL), urea (UV enzymat-
ic method - mg/dL), creatinine (kinetic Jaffe method 
- mg/dL), albumin (bromocresol green colorimetric 
method - g/dL), iron (ferrozine colorimetric method 
- µg/dL), total serum calcium (Arsenazo III method 
- mg/dL), serum phosphate (phosphomolybdate UV 
method - mg/dL), alkaline phosphatase (colorimetric 
method - modified from Bowers and McComb - U/L), 
iPTH (chemiluminescence method - pg/mL) and alu-
minum (atomic absorption spectroscopy method with 
Zeeman correction - µg/L).
The following drugs used in CKD-MBD therapy 
were also evaluated: phosphate binders (calcium 
carbonate, calcium acetate, and sevelamer), active 
vitamin D (calcitriol oral and venous), vitamin D 
analogues (alfacalcidol), selective vitamin D receptor 
activators (paricalcitol), and calcimimetics (cinacal-
cet). The number of parathyroidectomies conducted 
in 2013 was also recorded.
statIstIcal analysIs
A descriptive analysis was initially carried out and 
the data were reported by the mean±standard devia-
tion, median (interquartile range) or percentage, de-
pending on the variable. The population was divided 
based on iPTH levels (< 1 50; 151-300; 301-600; 
601-1000 > 1000 pg/mL) according to Douthat et al. 
who published a study based on 25 dialysis centers 
in Argentina15. The socio-demographic, clinical, and 
laboratorial data were compared between groups 
through ANOVA, chi-square or Mann-Whitney 
tests. The comparison between dialysis modality vs 
laboratorial variables and diabetes mellitus (yes and 
no) vs laboratorial variables by Student’s t-test or 
chi-square. Linear regression analysis was used to 
determine which variables influenced iPTH levels. 
Pearson’s or Spearman’s correlations were performed 
between the levels of iPTH and clinical and laborato-
ry variables. The criteria for inclusion in multivariate 
regression was statistical and/or clinical significance. 
iPTH dosage was used as the dependent variable and 
the following predictor variables were used in model 
1: age, diabetes mellitus, duration of therapy, and 
therapy modality. A confidence interval of 95% with 
p < 0.05 was used and the software was IBM’s SSPS 
15.0.
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Results
Of the 19 AMICEN dialysis centers invited to partici-
pate in the study, 11 provided data on their patients. 
Although 1219 patients were initially considered eli-
gible, 85 were later excluded from the study for one 
of the following reasons: less than 18 years old, on 
dialysis for less than 3 months or missing laboratorial 
iPTH dosage within the study period. Out of the 1134 
patients evaluated, the mean age was 57.3 ± 14.4 
years, varying from 19-96, 55.6% were males, 67% 
had elementary school education, and the monthly 
median income was US$ 274. The socio-demographic 
characteristics of the patients according to iPTH lev-
els are summarized in Table 1.
The main etiology of CKD was hypertensive ne-
phropathy (40.9%), followed by diabetic renal dis-
ease (24.3%). The majority of the patients presented 
with hypertension (80.4%), 32.9% were diabetic, 
and 11.8% had cardiovascular disease. Regarding di-
alysis treatment, 1071 patients were on HD (94.4%) 
and 63 were on PD (5.6%). The median duration of 
dialysis was 43 months (21-88), varying from 4 and 
274 months of therapy (Table 1). PD patients were 
analyzed separately and no difference was found com-
pared to the analysis in association with HD patients.
By comparing the different iPTH groups, it was 
observed that iPTH level decreases with increasing 
age (60.4 ± 14.9 vs. 51.4 ± 13.2, p < 0.0001). Patients 
who had diabetic kidney disease had a higher preva-
lence of iPTH lower than 150 pg/mL (27.6%) and a 
lower prevalence of iPTH greater than 1000 pg/mL 
(2.4%). Patients with diabetes mellitus, either as the 
cause of CKD or as comorbidity, had a higher preva-
lence of iPTH < 150 pg/mL (27.8%) and lower preva-
lence of iPTH > 1000 pg/mL (4.7%).
A higher percentage of patients with iPTH < 150 
pg/mL was found in PD compared with HD (33.3% 
vs. 22.8% with p = 0.19); however, the difference was 
statistically significant, probably due to the low num-
ber of patients on PD. A longer duration of therapy 
was associated with a higher iPTH serum level (53.7 
vs. 85.9 months with p < 0.001, Table 1).
The majority of the patients used calcium carbon-
ate as a phosphate binder (50.5%), and 14.7% used 
non-calcium-based binders (Sevelamer). Over 40% of 
the patients used active vitamin D (Calcitriol), vita-
min D analogues (Alfacalcidol) or selective vitamin D 
receptor activators (Paricalcitol) (Table 2).
Table 2 also shows that 44.3% of the patients 
with iPTH < 150 pg/mL were using calcium-based 
phosphate binders, of whom 14% used non-calcium-
based binders. In relation to vitamin D, the largest 
percentage of patients with iPTH > 600 pg/mL used 
intravenous calcitriol (55.7%). Patients with iPTH 
< 150pg/mL used some form of vitamin D (30.7%). 
Calcimimetics were used by 3.5% of the patients and 
72.5% had iPTH > 600 pg/mL.
Table 3 shows the laboratorial variables for the dif-
ferent iPTH levels. Urea and serum creatinine levels were 
lower in patients with iPTH < 150 pg/mL (p < 0.001), 
without differences in Kt/V (p = 0.34) or in serum albu-
min (p = 0.74). The levels of serum calcium, phosphate, 
and alkaline phosphatase increased with the increasing 
serum level of iPTH (p < 0.001 for all variables).
The median iPTH in the studied population was 
327.7 pg/mL (P25:161.2 pg/mL - P75: 647 pg/mL), 
varying from 1.3-3264 pg/mL. The prevalence of pa-
tients with iPTH > 600 pg/mL was 27.1% and with 
PTH < 150 pg/mL was 23.4%. Considering KDIGO 
targets for iPTH, 49.5% of the patients were in the 
150-600 pg/mL range. Mean serum calcium was 9.3 
± 0.9 mg/dL and serum phosphate 5.1 ± 1.6 mg/dL. 
Hyperphosphatemia (phosphate concentration above 
5.5 mg/dL) occurred in 35.8% of the studied popu-
lation and hypophosphatemia (phosphate concentra-
tion below 3.5 mg/dL) in 13.5%. Analysis of serum 
calcium showed that 39.3 % of the patients had a con-
centration above 9.5 mg/dL (hypercalcemia) while in 
12.6 % it was lower than 8.4 mg/dL (hypocalcemia).
Concerning therapy modality, 11.6% of patients 
on HD and 15.9% on PD had a iPTH above 1000 
pg/mL, with 33.3% of the patients on PD presenting 
a iPTH < 150 pg/mL (Table 1). Hyperphosphatemia 
had a high prevalence both in patients on HD 
(35.5%), and on PD (41.4%).
A significant positive correlation was observed 
between calcium concentration in the dialysate and 
iPTH levels (r = 0.08 p = 0.006), alkaline phosphatase 
(r = 0.490 p < 0.0001), and phosphorus (r = 0.234 p 
< 0.0001).
Linear regression analysis demonstrated a signifi-
cant negative association in model 1 between iPTH 
level and age and mellitus diabetes. The duration of 
therapy showed a significant positive association with 
the iPTH serum levels (Table 4). During 2013, there 
were no reports of parathyroidectomy in any of the 
patients of the study.
Braz. J. Nephrol. (J. Bras. Nefrol.) 2018;40(1):26-34
Chronic kidney disease and mineral bone disorder
30







(n = 265 - 23.4%)
150-300 
(n = 264 - 23.3%)
300-600 
(n = 298 - 26.2%)
600-1000 
(n = 173 - 15.3%)
> 1000 
(n = 134 - 11.8%)
Age (years) 
(Mean ± standard 
deviation)
60.4 ± 14.9a-b,c,d,e 58.3 ± 14.3b-a,c,d,e 57.6 ± 14.1c-a,b,d,e 55.9 ± 13.6d-a,b,c,e
51.4 ± 
13.2e-a,b,c,d
60.4 ± 14.9a-b,c,d,e < 0.001
Gender (%)
0.64Male 55.6 22.9 23.5 27.6 14.1 11.9
Female 44.4 24.1 24.5 24.5 16.7 11.7
Race (%)
< 0.001
White 48.9 23.4a-b,c,d,e 28.4b-a,c,d,e 25.0c-a,b,d,e 13.2d-a,b,c,e 10.0e-a,b,c,d
Black 24.9 18.9 15.7 28.5 19.9 17.1
Brown 26.2 27.8 20.7 26.4 14.9 10.2
Education (%)
0.26
Illiterate 8.1 18.1 30.6 27.8 19.4 4.2
Elementary School 67.0 20 22.4 30.5 16.0 11.1
High School 20.0 21.5 26.0 24.9 13.0 14.7
College 4.9 30.2 18.6 25.6 11.0 14.0
CKD etiology (%)
< 0.001
Hyp. Nephropathy# 40.9 23.9a-b,d,e 20.8b-a,c,d,e 24.9c-s,d,e 18.6d-a,b,c,e 11.8e-a,b,c,d
DRD# 24.3 27.6 26.4 32.9 10.6 2.4
GN# 13.7 16.5 20.9 23.7 19.4 19.4
APKD# 3.5 25.7 22.9 31.4 8.6 11.4
Unknown 4.6 12.8 19.1 31.9 14.9 21.3




80.4 22.8 22.1 26.5c-d,e 15.3 13.3 0.01
Diabetes Mellitus 32.9 27.8 26.4 29.5c-d,e 11.6 4.7 < 0.001
CVD* 11.8 23.1 22.2 29.9 15.4 9.4 0.84
Stroke 3.7 24.3 21.6 32.4 13.5 8.1 0.88
PVD* 5.7 22.8 28.1 29.8 15.8 3.5 0.24
COPD* 3.1 22.6 22.6 16.1 29.0 9.7 0.32
SLE* 1.5 26.7 20.0 13.3 33.3 6.7 0.39
Hepatic Cirrhosis 0.3 0 66.7 0 0 33.3 0.17
Others 34.3 23.0 26.8 25.9 14.5 9.8 0.50
Dialysis Modality (%)
Hemodialysis 94.4 22.8 23.7 26.4 15.5 11.6
0.17




(Mean ± standard 
deviation)
61.9 ± 54.0 53.7 ± 52.0a-b,d,e 55.2 ± 48b-a,c,d,e 53.5 ± 49.5c-b,d,e 80.7 ± 59.1d-a,b,c,e 85.9 ± 58.5e-a,b,c,d
Dialysate Calcium 
Concentration (%)
< 0.0013.5% 16.7 35.1 23.9 17.6 13.8 9.6
3.0% 37.4 27.0 22.0 22.9 16.1 12.1
2.5% 45.8 16.0 24.3 31.9 15.3 12.5
# Hyp. Nephropathy- Hypertensive Nephrophaty; DKD: diabetic kidney disease; GN: glomerulonephritis; APKD: adult polycystic kidney disease; *CVD: 
cardiovascular disease; PVD: peripheral vascular disease; COPD: chronic obstructive pulmonary disease; SLE: systemic lupus erythematosus.
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p< 150 150-300 300-600 600-1000 > 1000
(n = 265 - 23.4%) (n = 264 - 23.3%) (n = 298 - 26.2%) (n = 173 - 15.3%) (n = 134 - 11.8%)
Calcium Carbonate 50.5 27.0a-b,c,d,e 22.4b-a,c,d,e 26.3c-a,b,d,e 15.3d-a,b,c,e 9.1e-a,b,c,d 0.007
Calcium Acetate 5.1 17.3 34.6 19.2 15.4 13.5 0.28
Sevelamer* 14.7 14.0a-b,c,d,e 23.8b-a,c,d,e 20.1c-a,b,e 20.7d-a,b,e 21.3e-a,b,c,d < 0.001
Alfacalcidol** 18.7 13.3a-b,c,d,e 25.6b-a,c,d,e 30.3c-a,b,d,e 18.5d-a,b,c,e 12.3e-a,b,c,d 0.002
Calcitriol (oral)*** 8.0 10.1a-b,c,d 18.0b-a,c,d,e 41.6c-a,b,d,e 19.1d-a,b,c,e 11.2e-b,c,d 0.001
Calcitriol (venous)*** 13.5 7.3a-b,c,d,e 9.9b-a,c,d,e 27.2c-a,b,d,e 32.5d-a,b,c,e 23.2e-a,b,c,d < 0.001
Paricalcitol**** 0.2 0 50.0 0 0 50.0 0.35
Cinacalcet***** 3.5 2.5a-b,c,d,e 7.5b-a,c,e 17.5c-a,b,d,e 7.5d-b,c,e 65.0e-a,b,c,d < 0.001
Erythropoietin 83.1 22.9a-c,d,e 22.5b-c,d,e 25.4c-a,b,d,e 16.4d-a,b,c,e 12.8e-a,b,c,d 0.01
tAble 2 drug theraphy In patIents wIth cKd-MBd stratIfIed By theIr levels of pthI
*non-calcium-based binders; **vitamin D analogues; *** vitamin D oral and venous; ****vitamin D selective receptor activators; *****calcimimetic 
drugs.
dIscussIon
In this study the prevalence of patients with iPTH < 
150 pg/mL was 23.4% and with iPTH > 600 pg/mL 
was 27.1%. The phosphate binders used by the ma-
jority of patients in relation to the iPTH level were 
calcium-based, most had vitamin D by oral route, and 
a small percentage used calcimimetics and selective vi-
tamin D receptor activators.
Mean age and gender, and the main etiologies in 
our study are similar to those of the population on di-
alysis in Brazil4 and in Argentina, as shown in a study 
published in 2013, which reported on 1210 patients 
from 25 dialysis centers, with a mean age of 55.3 ± 
17.6 years and 60.8% of males15.
The sample used in this study represents around 
1% of the Brazilian population on dialysis in 20134. 
Regarding the modality of dialysis, our study had 
less patients on PD compared to the 2013 Brazilian 
Chronic Dialysis Survey (5.6% vs. 9.2%)4.
A study conducted with 5008 patients on dialy-
sis in Hungary demonstrated an inverse relationship 
between age and iPTH levels, regardless of diabetes 
mellitus16. Our results corroborate this conclusion, 
showing that age is inversely associated with iPTH 
level. This is probably due to a higher prevalence of 
low remodeling bone disorders13,17.
Race in the Brazilian population is a complex and 
controversial subject, since Brazil has the largest mis-
cegenation in the world18. The lowest levels of iPTH 
in white and brown individuals and the highest levels 
in black individuals as observed in our study do not 
allow inferences about the general Brazilian popula-
tion. As demonstrated by Dos Reis et al. in bone biop-
sies of individuals without CKD, histomorphometric 
analysis results showed no association with gender 
and race in Brazil19. A study performed in the United 
States with 2056 patients reported that black patients 
in pre-dialytic and dialytic stages had lower serum 
levels of 25 hydroxyvitamin D and higher levels of 
iPTH when compared to white patients20. In a US 
study with 139,328 patients including 32% African-
Americans on thrice weekly hemodialysis treatment 
in a single large dialysis organization, most labo-
ratory values were measured monthly for up to 60 
months (July 2001 to June 2006). The study found 
that African-Americans had higher serum calcium 
and PTH levels but similar concentrations of phos-
phorus and alkaline phosphatase and were more like-
ly to receive injectable active vitamin D medications 
and at higher doses than their non-African-American 
counterparts21.
Diabetes Mellitus is known to be associated with 
low-remodeling bone disorder12,16,22. In our study, 
39.3% of the patients with PTHi levels below 150 pg/
mL had diabetes mellitus, consistent with the recent 
review by Bover et al., in which low-remodeling bone 
disorder was associated, among other diseases, with 
diabetes mellitus13. Diabetes patients with CKD have 
lower rates of bone formation, a complication that 
often precedes CKD development. In these patients, 
there is a deficiency of vitamin D and an increase of 
advanced glycated end-products (AGE) as well as a 
decrease in osteoblast lifespan22. Concerning therapy 
modality, several authors have found lower levels of 
PTHi in PD than in HD23,24. However, no difference 
was observed in our study, probably due to the low 
number of patients on PD.
High-remodeling bone disorder develops early 
during CKD and continues evolving when patients 
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(n = 265 - 
23.4%)
150-300
(n = 264 - 
23.3%)
300-600
(n = 298 - 
26.2%)
600-1000
(n = 173 - 
15.3%)
> 1000
(n = 134 - 
11.8%)
Urea (mg/dL) 118.5 ± 37.8 110.7 ± 37.5a-b,c,d,e 115.9 ± 35.3b-a,c,d,e 119.8 ± 38.5c-a,b,d,e 126.5 ± 38.9d-a,b,c 125.3 ± 36.9e-a,b,c, < 0.001
Creatinine (mg/dL) 9.1 ± 3.5 8.0 ± 3.1a-b,c,d,e 8.6 ± 3.3b-a,c,d,e 9.7 ± 4.2c-a,b,d,e 10.0 ± 2.9d-a,b,c 10.2 ± 3.1e-a,b,c < 0.001
Calcium (mg/dL) 9.3 ± 0.9 9.5 ± 1.0a,c 9.3 ± 0.9 9.1 ± 0.9c,a,e 9.4 ± 0.9 9.5 ± 0.8e,c < 0.001
Phosphorus (mg/dL) 5.1 ± 1.6 4.8 ± 1.4a-c,d,e 4.8 ± 1.4b-c,d,e 5.2 ± 1.7c-a,b,d,e 5.5 ± 1.6d-a,b,c,e 5.8 ± 1.6e-a,b,c,d < 0.001
Hemoglobin (g/dL) 11.0 ± 2.3 10.9 ± 1.9 11.0±1.9 11.2± 3.3 11.2 ± 1.7 10.6 ± 1.7 0.14
Albumin (g/dL) 3.8 ± 0.4 3.86 ± 0.5 3.88 ± 0.4 3.88 ± 0.4 3.83 ± 0.4 3.83 ± 0.4 0.74
Iron (µg/dL) 74.1 ± 39.0 70.20 ± 34.7 75.21 ± 38.5 76.03 ± 35.1 74.57 ± 38.9 75.09 ± 53.7 0.45
Ferritin (ng/mL) 510.0 ± 402.9 511.4 ± 394.3 514.8 ± 394.1 508.0 ± 377.5 491.8 ± 443.7 526.3 ± 440.4 0.96
Alk. Phos. (U/L)# 199.7 ± 243.1 121.9 ± 101.4a-b,c,d,e 150.8 ± 150.3b-a,c,d,e 173.3 ± 143.3c-a,b,d,e 228.7 ±245.0d-a,b,c,e 470.4 ± 470.1e-a,b,c,d < 0.001
Aluminum (ug/L) 10.6 ± 7.0 11.2 ± 7.1 10.2 ± 6.2 10.5 ± 7.7 11.4 ± 7.4 9.1 ± 5.6 0.05
Kt/V 1.49 ±0.48 1.45 ± 0.51 1.54 ± 0.52 1.49 ± 0.48 1.49 ± 0.40 1.51 ± 0.37 0.34
tAble 3 laBoratorIal varIaBles and Kt/v expressed as Mean ± sd In the patIents studIed who were stratIfIed By   
 theIr levels of pthI
# Alk. Phos. - Alkaline Phosphatase.
Model 1 Beta Sig
Confidence interval 95 % for B
Inferior limit Superior limit
Age -0.161 0.000 -7.235 -3.410
Diabetes Mellitus (yes) -0.104 0.001 -165.884 -45.411
Time of therapy 0.188 0.000 1.130 2.170
Dialysis Modality (hemodialysis) 0.055 0.060 -5.294 245.816
tAble 4 lInear regressIon usIng the pthI level as dependent varIaBle
start dialytic therapy25. This was also observed in this 
study: a higher prevalence of serum iPTH levels was as-
sociated with longer therapy duration.
Regarding drug usage, we found a high percentage of 
patients using calcium-based phosphate binders (55.6%), 
consistent with the study by Tentori et al., through DOPPS 
I, II, and III data analysis of 25,558 patients on hemo-
dialysis, which showed a high percentage of these drugs 
(72.9%)26. Those authors also found that 17.1% used 
sevelamer compared with 14.7% found in our study. 
The 2013 Brazilian Chronic Dialysis Survey indicates a 
higher usage (38%) of non-calcium phosphate binders 
(Sevelamer)4, in disagreement with our study, probably 
due to problems of the public health care system related to 
drug distribution.
The usage of active vitamin D and analogues (oral and 
venous calcitriol, alfacalcidol, paricalcitol) in the popula-
tion studied was 40.2%. However, when analyzing distinct 
iPTH groups, we observed that 46.7% of the patients with 
iPTH > 1000 pg/mL used these drugs, while in patients 
with iPTH < 150 pg/mL 30.7% used them. Because of the 
cross-sectional nature of this study, some patients might 
have had a decrease in iPTH associated with the usage of 
vitamin D or previous (before 2013) parathyroidecto-
my. Compared to other studies, the use of vitamin D in 
the present study was low. For instance, in the study by 
Tentori et al., vitamin D was prescribed to 52% of the 
patients, although this was not analyzed as a function 
of iPTH level26. An Argentinian study revealed that 
59.3% of the patients with iPTH > 300 pg/mL, and 
36.9% of the patients with iPTH < 150 pg/mL used 
active vitamin D or its analogues15.
Taking into consideration the large number of pa-
tients with hyperparathyroidism in our study, calcimi-
metics (Cinacalcet) were underutilized, probably be-
cause, even though they are available in Brazil, these 
drugs are still not freely distributed through the public 
health care network, unlike calcitriol and other active 
vitamin D analogues (e.g., alfacalcidol). Similarly, the 
low usage of selective vitamin D receptors activators 
might be due to same reason.
There was no record of aluminum-based binders 
in the population studied, and hemodialysis is per-
formed through reverse osmosis in the 11 nephrol-
ogy centers. Aluminum serum levels were associated 
with lower iPTH levels in our study. Several authors 
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question whether distinct aluminum sources, such as 
aluminum household utensils, parenteral solutions or 
foods, could explain this fact27-29.
Concerning the dialysate calcium concentrate 
(DCC), a recent study by Jean and Chazot on hemo-
dialysis shows that different regions of the world have 
various strategies in relation to this topic. Decreasing 
the DCC slightly reduces calcemia, but mainly stimu-
lates parathyroid hormone secretion and bone turn-
over. Conversely, increasing the DCC increases cal-
cemia slightly and reduces parathyroid hormone 
secretion and bone turnover markedly. Furthermore, 
higher DCCs favor hemodynamic stability and can 
prevent ventricular arrhythmias. Even though some 
studies have shown that using individualized DCCs of 
1.25 or 1.75mmol/L is not harmful, the real benefits 
of this strategy need to be assessed in a large, mul-
ticenter trial30. In peritoneal dialysis, long-term (1-2 
year) use of low-calcium dialysate (LCD) with 1.25 
mmol/L calcium concentration results in decreased 
serum total and ionized calcium levels and has no ef-
fect on phosphate level. No clinical significance in the 
low calcium change of standard calcium (SCD) bone 
metabolism was observed between LCD and SCD pa-
tients despite low calcium the increase of serum para-
thyroid hormone in LCD group31.
Based on the 2011 Brazilian Census of 
Parathyroidectomy, 10.7% of the patients on dialysis 
presented an iPTH > 1000 pg/mL9, which is in agree-
ment with the results found in our study (11.8%). 
There is no accurate data on the number of parathy-
roidectomies performed in Brazil. However, a study in 
Argentina, with a population sample of 1210 patients, 
showed that 70 patients (5.8%) had been submitted 
to this procedure15. As mentioned, no references to 
parathyroidectomies were found in the records ana-
lyzed in our study.
The cross-sectional design of this study is a limita-
tion and therefore some inferences cannot be made. 
Ionic calcium was not measured and only one iPTH 
measurement was performed. The importance of the 
present study is that, first, it looks at the reality of the 
dialysis units that serve a large part of the population; 
and second, it provides a general idea of practice pat-
terns in Brazil, since it does not focus exclusively on 
data from symptomatic patients or from patients fol-
lowed up in a CKD-MBD reference center.
We can conclude that the prevalence of pa-
tients outside the KDIGO iPTH target was 50.5%. 
Hyperphosphatemia occurred in 35.8% of the stud-
ied population and hypophosphatemia in 13.5%. 
Analysis of the serum calcium showed that 39.3% of 
the patients had hypercalcemia while 12.6 % present-
ed with hypocalcemia. There was low usage of active 
vitamin D, selective vitamin D receptors activators, 
and calcimimetic drugs. These data draw attention to 
the need for stronger compliance with public policies 
and guidelines regarding the supply of drugs associ-
ated with CKD-MBD.
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